Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Health Care Costs | 55 | 2024 | 3242 | 3.770 |
Why?
|
Hemoglobinuria, Paroxysmal | 5 | 2023 | 86 | 2.680 |
Why?
|
Medication Adherence | 17 | 2024 | 2192 | 2.390 |
Why?
|
Cost of Illness | 21 | 2024 | 1950 | 2.360 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 17 | 2024 | 3247 | 2.140 |
Why?
|
Adrenal Cortex Hormones | 21 | 2024 | 1880 | 2.020 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 31 | 2024 | 11868 | 1.720 |
Why?
|
Bronchodilator Agents | 9 | 2024 | 514 | 1.650 |
Why?
|
Erythropoietin | 13 | 2009 | 716 | 1.650 |
Why?
|
Retrospective Studies | 180 | 2024 | 81514 | 1.640 |
Why?
|
Neurofibroma, Plexiform | 2 | 2024 | 66 | 1.630 |
Why?
|
Anti-Asthmatic Agents | 10 | 2024 | 572 | 1.460 |
Why?
|
Adrenergic beta-2 Receptor Agonists | 9 | 2024 | 109 | 1.450 |
Why?
|
Health Resources | 14 | 2024 | 949 | 1.400 |
Why?
|
Managed Care Programs | 9 | 2014 | 934 | 1.400 |
Why?
|
Hospitalization | 28 | 2024 | 10808 | 1.380 |
Why?
|
Insurance Claim Review | 18 | 2024 | 746 | 1.290 |
Why?
|
Anemia | 15 | 2009 | 1511 | 1.260 |
Why?
|
Administration, Inhalation | 15 | 2024 | 1154 | 1.260 |
Why?
|
Absenteeism | 5 | 2020 | 246 | 1.260 |
Why?
|
Muscarinic Antagonists | 6 | 2024 | 133 | 1.210 |
Why?
|
Neurofibromatosis 1 | 2 | 2024 | 560 | 1.180 |
Why?
|
Chlorobenzenes | 6 | 2022 | 31 | 1.170 |
Why?
|
Phenylurea Compounds | 6 | 2021 | 536 | 1.160 |
Why?
|
Anticonvulsants | 14 | 2021 | 1921 | 1.150 |
Why?
|
Asthma | 18 | 2024 | 6270 | 1.150 |
Why?
|
Cardiac Resynchronization Therapy | 3 | 2022 | 562 | 1.090 |
Why?
|
United States | 101 | 2024 | 72903 | 1.070 |
Why?
|
Patient Acceptance of Health Care | 16 | 2024 | 3230 | 1.000 |
Why?
|
Trifluridine | 3 | 2021 | 27 | 1.000 |
Why?
|
Multiple Myeloma | 9 | 2024 | 5197 | 0.970 |
Why?
|
Chelation Therapy | 5 | 2018 | 77 | 0.960 |
Why?
|
Kidney Neoplasms | 15 | 2023 | 4274 | 0.950 |
Why?
|
Melanoma | 6 | 2019 | 5719 | 0.940 |
Why?
|
Herpes Zoster | 4 | 2024 | 252 | 0.930 |
Why?
|
Middle Aged | 152 | 2024 | 223009 | 0.920 |
Why?
|
Epilepsy | 12 | 2021 | 3320 | 0.910 |
Why?
|
Pyrroles | 5 | 2022 | 1119 | 0.900 |
Why?
|
Imidazoles | 6 | 2018 | 1162 | 0.890 |
Why?
|
Aged | 128 | 2024 | 171117 | 0.890 |
Why?
|
Longitudinal Studies | 36 | 2024 | 14751 | 0.870 |
Why?
|
Male | 182 | 2024 | 363698 | 0.860 |
Why?
|
Drugs, Generic | 7 | 2010 | 456 | 0.860 |
Why?
|
Antipsychotic Agents | 10 | 2017 | 3076 | 0.820 |
Why?
|
5-alpha Reductase Inhibitors | 2 | 2021 | 114 | 0.820 |
Why?
|
Drug Combinations | 13 | 2024 | 2077 | 0.810 |
Why?
|
Carcinoma, Renal Cell | 10 | 2023 | 3181 | 0.810 |
Why?
|
Female | 179 | 2024 | 396112 | 0.800 |
Why?
|
Humans | 262 | 2024 | 765968 | 0.800 |
Why?
|
Iron Chelating Agents | 5 | 2019 | 142 | 0.790 |
Why?
|
Adrenergic alpha-1 Receptor Antagonists | 1 | 2021 | 23 | 0.780 |
Why?
|
Adult | 126 | 2024 | 223044 | 0.770 |
Why?
|
Rotavirus Infections | 3 | 2017 | 85 | 0.770 |
Why?
|
Indoles | 4 | 2014 | 1839 | 0.760 |
Why?
|
Insurance, Disability | 2 | 2019 | 26 | 0.760 |
Why?
|
Disease Progression | 13 | 2024 | 13632 | 0.740 |
Why?
|
Medicaid | 14 | 2020 | 2833 | 0.740 |
Why?
|
Thymine | 3 | 2021 | 69 | 0.740 |
Why?
|
Drug Costs | 11 | 2010 | 1193 | 0.730 |
Why?
|
Angiogenesis Inhibitors | 6 | 2014 | 2056 | 0.710 |
Why?
|
Industry | 2 | 2020 | 362 | 0.710 |
Why?
|
Hematinics | 7 | 2009 | 282 | 0.710 |
Why?
|
Prostatic Hyperplasia | 2 | 2021 | 515 | 0.680 |
Why?
|
Databases, Factual | 21 | 2022 | 8067 | 0.670 |
Why?
|
Hypoglycemic Agents | 8 | 2018 | 3110 | 0.670 |
Why?
|
Diphosphonates | 3 | 2010 | 625 | 0.650 |
Why?
|
Insurance, Health | 15 | 2021 | 2521 | 0.650 |
Why?
|
Pyrrolidines | 3 | 2021 | 337 | 0.650 |
Why?
|
Administration, Oral | 14 | 2024 | 4015 | 0.640 |
Why?
|
Weight Loss | 5 | 2018 | 2710 | 0.620 |
Why?
|
Anemia, Sickle Cell | 4 | 2015 | 1067 | 0.620 |
Why?
|
Malignant Carcinoid Syndrome | 5 | 2019 | 31 | 0.620 |
Why?
|
Candidiasis, Invasive | 1 | 2018 | 27 | 0.610 |
Why?
|
Adrenergic beta-Agonists | 2 | 2021 | 345 | 0.600 |
Why?
|
Echinocandins | 1 | 2018 | 57 | 0.600 |
Why?
|
Anemia, Aplastic | 1 | 2020 | 232 | 0.580 |
Why?
|
Benzyl Alcohols | 6 | 2022 | 33 | 0.580 |
Why?
|
Blood Transfusion | 9 | 2020 | 1297 | 0.570 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 5 | 2024 | 1646 | 0.570 |
Why?
|
Cohort Studies | 49 | 2024 | 41649 | 0.570 |
Why?
|
Pyridines | 5 | 2021 | 2888 | 0.570 |
Why?
|
Nebulizers and Vaporizers | 4 | 2022 | 138 | 0.560 |
Why?
|
Health Services | 5 | 2017 | 756 | 0.550 |
Why?
|
Bone Density Conservation Agents | 3 | 2010 | 791 | 0.550 |
Why?
|
Treatment Outcome | 55 | 2024 | 65188 | 0.540 |
Why?
|
Dexamethasone | 5 | 2024 | 1963 | 0.540 |
Why?
|
Niacinamide | 3 | 2013 | 419 | 0.530 |
Why?
|
Sodium Potassium Chloride Symporter Inhibitors | 2 | 2015 | 157 | 0.530 |
Why?
|
Cyclobutanes | 1 | 2016 | 57 | 0.520 |
Why?
|
Pyridones | 3 | 2021 | 816 | 0.520 |
Why?
|
Molecular Targeted Therapy | 5 | 2024 | 2822 | 0.520 |
Why?
|
Urinary Retention | 2 | 2016 | 100 | 0.510 |
Why?
|
Skin Neoplasms | 4 | 2023 | 5849 | 0.500 |
Why?
|
Pericarditis | 3 | 2022 | 137 | 0.500 |
Why?
|
Antineoplastic Agents | 14 | 2022 | 13648 | 0.500 |
Why?
|
Quinuclidines | 4 | 2022 | 27 | 0.480 |
Why?
|
Schizophrenia | 9 | 2017 | 6972 | 0.470 |
Why?
|
Costs and Cost Analysis | 12 | 2019 | 1668 | 0.450 |
Why?
|
Body Weight | 4 | 2023 | 4622 | 0.440 |
Why?
|
Venous Thromboembolism | 7 | 2018 | 1882 | 0.430 |
Why?
|
Proton Pump Inhibitors | 2 | 2009 | 553 | 0.430 |
Why?
|
Benzenesulfonates | 2 | 2011 | 170 | 0.430 |
Why?
|
Models, Economic | 5 | 2017 | 716 | 0.430 |
Why?
|
Ambulatory Care | 4 | 2017 | 2778 | 0.430 |
Why?
|
Kaplan-Meier Estimate | 16 | 2021 | 6499 | 0.430 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 6 | 2023 | 5389 | 0.430 |
Why?
|
Patient Compliance | 5 | 2019 | 2692 | 0.420 |
Why?
|
Vasodilator Agents | 2 | 2015 | 988 | 0.420 |
Why?
|
Aged, 80 and over | 37 | 2024 | 59489 | 0.420 |
Why?
|
Complement Inactivating Agents | 2 | 2023 | 53 | 0.420 |
Why?
|
Insurance, Physician Services | 1 | 2013 | 23 | 0.420 |
Why?
|
Drug Therapy, Combination | 11 | 2022 | 6309 | 0.420 |
Why?
|
Heart Failure | 6 | 2022 | 11840 | 0.420 |
Why?
|
Hodgkin Disease | 1 | 2021 | 1383 | 0.410 |
Why?
|
Diabetes Mellitus, Type 2 | 10 | 2019 | 12240 | 0.410 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 1 | 2017 | 318 | 0.410 |
Why?
|
Contraception | 1 | 2016 | 361 | 0.410 |
Why?
|
Status Epilepticus | 2 | 2019 | 460 | 0.410 |
Why?
|
Young Adult | 37 | 2024 | 59889 | 0.410 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2016 | 497 | 0.410 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2019 | 790 | 0.410 |
Why?
|
Obesity | 4 | 2023 | 13076 | 0.410 |
Why?
|
Defibrillators, Implantable | 1 | 2022 | 1490 | 0.410 |
Why?
|
Protein Kinase Inhibitors | 6 | 2024 | 5696 | 0.400 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2019 | 2054 | 0.400 |
Why?
|
Early Diagnosis | 2 | 2014 | 1187 | 0.400 |
Why?
|
Kidney Failure, Chronic | 5 | 2008 | 2495 | 0.390 |
Why?
|
Blood Pressure | 5 | 2018 | 8532 | 0.390 |
Why?
|
Octreotide | 3 | 2019 | 157 | 0.390 |
Why?
|
Renal Insufficiency | 2 | 2008 | 804 | 0.390 |
Why?
|
Menorrhagia | 1 | 2012 | 59 | 0.380 |
Why?
|
Angiomyolipoma | 3 | 2018 | 190 | 0.380 |
Why?
|
Rotavirus Vaccines | 3 | 2017 | 62 | 0.380 |
Why?
|
Somatostatin | 5 | 2019 | 459 | 0.370 |
Why?
|
Adolescent | 42 | 2024 | 88835 | 0.370 |
Why?
|
Quality Indicators, Health Care | 2 | 2021 | 1806 | 0.370 |
Why?
|
Immunosuppressive Agents | 3 | 2022 | 4209 | 0.370 |
Why?
|
Central Nervous System Stimulants | 1 | 2020 | 1167 | 0.370 |
Why?
|
Triazines | 4 | 2022 | 307 | 0.370 |
Why?
|
Health Expenditures | 7 | 2017 | 2387 | 0.370 |
Why?
|
Efficiency | 3 | 2020 | 480 | 0.370 |
Why?
|
Anti-HIV Agents | 2 | 2024 | 4559 | 0.370 |
Why?
|
Risperidone | 1 | 2013 | 383 | 0.370 |
Why?
|
Phenylcarbamates | 1 | 2010 | 38 | 0.360 |
Why?
|
Lupus Erythematosus, Systemic | 3 | 2023 | 2159 | 0.360 |
Why?
|
Hemoglobins | 5 | 2023 | 1530 | 0.360 |
Why?
|
Fructose | 2 | 2010 | 286 | 0.350 |
Why?
|
Epoetin Alfa | 9 | 2009 | 78 | 0.350 |
Why?
|
Lung Neoplasms | 10 | 2023 | 13451 | 0.340 |
Why?
|
Indans | 1 | 2010 | 92 | 0.340 |
Why?
|
Hypertension | 5 | 2018 | 8626 | 0.340 |
Why?
|
Electronic Health Records | 10 | 2024 | 4873 | 0.330 |
Why?
|
Escherichia coli Infections | 2 | 2024 | 519 | 0.330 |
Why?
|
Acetaminophen | 2 | 2010 | 547 | 0.330 |
Why?
|
Administration, Cutaneous | 3 | 2018 | 715 | 0.320 |
Why?
|
Hand Dermatoses | 2 | 2006 | 61 | 0.320 |
Why?
|
Quality of Life | 11 | 2023 | 13462 | 0.310 |
Why?
|
Severity of Illness Index | 14 | 2024 | 15880 | 0.310 |
Why?
|
Neuroendocrine Tumors | 5 | 2019 | 654 | 0.310 |
Why?
|
Cholinesterase Inhibitors | 1 | 2010 | 241 | 0.310 |
Why?
|
Antihypertensive Agents | 3 | 2013 | 2033 | 0.310 |
Why?
|
Carcinoma, Small Cell | 2 | 2008 | 420 | 0.310 |
Why?
|
Suicide | 1 | 2020 | 1604 | 0.310 |
Why?
|
European Union | 1 | 2009 | 157 | 0.300 |
Why?
|
Bone Neoplasms | 4 | 2020 | 2567 | 0.300 |
Why?
|
Recurrence | 10 | 2024 | 8501 | 0.300 |
Why?
|
Recombinant Proteins | 12 | 2009 | 6493 | 0.290 |
Why?
|
Benzoates | 2 | 2020 | 213 | 0.290 |
Why?
|
Hydrazines | 2 | 2020 | 223 | 0.290 |
Why?
|
Colorectal Neoplasms | 4 | 2021 | 6942 | 0.290 |
Why?
|
Nitriles | 5 | 2021 | 982 | 0.280 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2009 | 318 | 0.280 |
Why?
|
Incidence | 15 | 2024 | 21480 | 0.280 |
Why?
|
HIV Infections | 3 | 2024 | 17533 | 0.280 |
Why?
|
Urinary Tract Infections | 2 | 2024 | 805 | 0.280 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2019 | 2176 | 0.280 |
Why?
|
HIV-1 | 1 | 2024 | 6944 | 0.280 |
Why?
|
Erythropoiesis | 2 | 2008 | 691 | 0.280 |
Why?
|
Cost-Benefit Analysis | 7 | 2023 | 5526 | 0.270 |
Why?
|
Work | 2 | 2020 | 195 | 0.270 |
Why?
|
Follow-Up Studies | 19 | 2024 | 39193 | 0.270 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2009 | 633 | 0.270 |
Why?
|
Thalassemia | 2 | 2019 | 267 | 0.270 |
Why?
|
Medicare | 8 | 2023 | 6823 | 0.270 |
Why?
|
Prospective Payment System | 1 | 2007 | 135 | 0.260 |
Why?
|
Bone Diseases | 1 | 2010 | 411 | 0.260 |
Why?
|
Iron | 1 | 2014 | 1816 | 0.260 |
Why?
|
Neoplasm Recurrence, Local | 5 | 2024 | 9373 | 0.260 |
Why?
|
Vaccination | 5 | 2019 | 3426 | 0.260 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2009 | 891 | 0.260 |
Why?
|
Androstadienes | 3 | 2022 | 347 | 0.260 |
Why?
|
Boron Compounds | 2 | 2024 | 196 | 0.250 |
Why?
|
Pyridazines | 2 | 2018 | 200 | 0.250 |
Why?
|
Renal Dialysis | 4 | 2008 | 1799 | 0.250 |
Why?
|
Azithromycin | 2 | 2022 | 201 | 0.250 |
Why?
|
Algorithms | 6 | 2024 | 14071 | 0.240 |
Why?
|
Body Mass Index | 3 | 2019 | 13039 | 0.240 |
Why?
|
Medical Records | 6 | 2019 | 1409 | 0.240 |
Why?
|
International Classification of Diseases | 4 | 2022 | 935 | 0.240 |
Why?
|
Estrogens | 3 | 2018 | 1529 | 0.230 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2020 | 3719 | 0.230 |
Why?
|
Multivariate Analysis | 15 | 2019 | 12056 | 0.230 |
Why?
|
Drug Administration Schedule | 4 | 2019 | 4850 | 0.230 |
Why?
|
Pregnancy, Unplanned | 2 | 2016 | 86 | 0.230 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2007 | 409 | 0.230 |
Why?
|
Kidney Diseases | 3 | 2010 | 2098 | 0.230 |
Why?
|
Neutropenia | 1 | 2009 | 893 | 0.230 |
Why?
|
Sick Leave | 2 | 2020 | 105 | 0.230 |
Why?
|
Gastroesophageal Reflux | 2 | 2009 | 833 | 0.230 |
Why?
|
Glycine | 2 | 2024 | 672 | 0.220 |
Why?
|
Mutation | 5 | 2024 | 30198 | 0.220 |
Why?
|
Dermatitis | 1 | 2006 | 199 | 0.220 |
Why?
|
Neoplasm Metastasis | 6 | 2024 | 4893 | 0.220 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2007 | 390 | 0.220 |
Why?
|
Europe | 4 | 2023 | 3423 | 0.220 |
Why?
|
Proportional Hazards Models | 8 | 2022 | 12509 | 0.220 |
Why?
|
Health Maintenance Organizations | 1 | 2006 | 656 | 0.220 |
Why?
|
SEER Program | 3 | 2019 | 1446 | 0.220 |
Why?
|
Polypharmacy | 2 | 2020 | 306 | 0.220 |
Why?
|
Eosinophils | 2 | 2018 | 945 | 0.220 |
Why?
|
Pain | 3 | 2023 | 5077 | 0.210 |
Why?
|
Immunotherapy | 1 | 2019 | 4752 | 0.210 |
Why?
|
Lung | 2 | 2019 | 10033 | 0.210 |
Why?
|
Complement C5 | 1 | 2023 | 99 | 0.210 |
Why?
|
Risk Factors | 19 | 2024 | 74840 | 0.210 |
Why?
|
Cardiovascular Diseases | 7 | 2024 | 15652 | 0.200 |
Why?
|
Androgen Antagonists | 2 | 2024 | 1411 | 0.200 |
Why?
|
Androstenes | 3 | 2021 | 178 | 0.200 |
Why?
|
Age Factors | 7 | 2020 | 18380 | 0.200 |
Why?
|
Cancer Care Facilities | 4 | 2021 | 426 | 0.200 |
Why?
|
Phenylthiohydantoin | 3 | 2021 | 206 | 0.200 |
Why?
|
Amoxicillin-Potassium Clavulanate Combination | 1 | 2022 | 32 | 0.200 |
Why?
|
Hypereosinophilic Syndrome | 1 | 2023 | 97 | 0.200 |
Why?
|
Carcinoid Tumor | 2 | 2019 | 225 | 0.200 |
Why?
|
Iron Overload | 2 | 2018 | 245 | 0.200 |
Why?
|
Mycosis Fungoides | 1 | 2023 | 155 | 0.200 |
Why?
|
Piperidines | 1 | 2010 | 1664 | 0.190 |
Why?
|
Vaccines, Attenuated | 3 | 2017 | 312 | 0.190 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 1 | 2023 | 196 | 0.190 |
Why?
|
Taxoids | 3 | 2024 | 665 | 0.180 |
Why?
|
Cardiac Resynchronization Therapy Devices | 1 | 2022 | 122 | 0.180 |
Why?
|
Comorbidity | 12 | 2021 | 10563 | 0.180 |
Why?
|
Pyrazoles | 3 | 2022 | 2033 | 0.180 |
Why?
|
Child | 23 | 2022 | 80564 | 0.180 |
Why?
|
Mastocytosis, Systemic | 1 | 2022 | 102 | 0.180 |
Why?
|
Estrogen Replacement Therapy | 3 | 2018 | 1206 | 0.180 |
Why?
|
Emergency Service, Hospital | 6 | 2015 | 7875 | 0.180 |
Why?
|
Disability Evaluation | 1 | 2008 | 1820 | 0.170 |
Why?
|
Antibodies, Anti-Idiotypic | 2 | 2012 | 340 | 0.170 |
Why?
|
Peptides, Cyclic | 2 | 2019 | 390 | 0.170 |
Why?
|
Diphtheria-Tetanus-acellular Pertussis Vaccines | 2 | 2018 | 39 | 0.170 |
Why?
|
Paris | 1 | 2020 | 40 | 0.170 |
Why?
|
Respiratory Tract Infections | 1 | 2008 | 1008 | 0.170 |
Why?
|
Quebec | 2 | 2012 | 140 | 0.170 |
Why?
|
Radium | 1 | 2020 | 70 | 0.170 |
Why?
|
Antirheumatic Agents | 2 | 2023 | 1365 | 0.170 |
Why?
|
Accidental Falls | 1 | 2008 | 1078 | 0.160 |
Why?
|
Carcinoma | 1 | 2011 | 2312 | 0.160 |
Why?
|
Republic of Korea | 1 | 2021 | 588 | 0.160 |
Why?
|
Pregnancy Complications | 1 | 2013 | 2975 | 0.160 |
Why?
|
Erythrocyte Transfusion | 4 | 2015 | 568 | 0.160 |
Why?
|
Neoplasms | 8 | 2015 | 22340 | 0.160 |
Why?
|
Boronic Acids | 2 | 2014 | 916 | 0.160 |
Why?
|
Renal Insufficiency, Chronic | 3 | 2019 | 2310 | 0.160 |
Why?
|
Veterans | 4 | 2023 | 2664 | 0.160 |
Why?
|
Anti-Obesity Agents | 1 | 2023 | 242 | 0.160 |
Why?
|
Dermatitis, Atopic | 2 | 2022 | 729 | 0.160 |
Why?
|
Herpesvirus 3, Human | 2 | 2023 | 159 | 0.160 |
Why?
|
Marketing | 1 | 2021 | 225 | 0.160 |
Why?
|
Tuberous Sclerosis | 2 | 2018 | 1038 | 0.160 |
Why?
|
Time Factors | 11 | 2019 | 40065 | 0.160 |
Why?
|
Workers' Compensation | 1 | 2019 | 150 | 0.160 |
Why?
|
Legislation, Drug | 1 | 2021 | 217 | 0.160 |
Why?
|
BRCA2 Protein | 1 | 2024 | 800 | 0.160 |
Why?
|
Survival Analysis | 9 | 2017 | 10070 | 0.160 |
Why?
|
Meningococcal Vaccines | 1 | 2019 | 96 | 0.160 |
Why?
|
Hormone Antagonists | 1 | 2019 | 108 | 0.160 |
Why?
|
Population Surveillance | 3 | 2018 | 2590 | 0.150 |
Why?
|
Antibodies, Monoclonal | 5 | 2024 | 9249 | 0.150 |
Why?
|
Canada | 4 | 2021 | 2119 | 0.150 |
Why?
|
Benzimidazoles | 1 | 2024 | 864 | 0.150 |
Why?
|
Myelodysplastic Syndromes | 3 | 2019 | 1404 | 0.150 |
Why?
|
Cystic Fibrosis | 1 | 2008 | 1287 | 0.150 |
Why?
|
Immunization Schedule | 2 | 2019 | 228 | 0.150 |
Why?
|
Neoplasm Staging | 5 | 2020 | 11206 | 0.150 |
Why?
|
Dosage Forms | 1 | 2018 | 55 | 0.150 |
Why?
|
Comparative Effectiveness Research | 3 | 2024 | 714 | 0.150 |
Why?
|
Benzamides | 3 | 2021 | 1377 | 0.150 |
Why?
|
Survival Rate | 7 | 2024 | 12795 | 0.150 |
Why?
|
Diarrhea | 4 | 2023 | 1316 | 0.150 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2018 | 1560 | 0.150 |
Why?
|
Diabetic Nephropathies | 2 | 2019 | 969 | 0.150 |
Why?
|
Hepatitis B, Chronic | 1 | 2022 | 412 | 0.150 |
Why?
|
Dose-Response Relationship, Drug | 7 | 2017 | 10729 | 0.150 |
Why?
|
Vagus Nerve Stimulation | 2 | 2012 | 228 | 0.150 |
Why?
|
Antilymphocyte Serum | 1 | 2020 | 493 | 0.150 |
Why?
|
Drug Delivery Systems | 1 | 2009 | 2207 | 0.150 |
Why?
|
Health Care Sector | 1 | 2020 | 196 | 0.150 |
Why?
|
Activities of Daily Living | 2 | 2020 | 2415 | 0.150 |
Why?
|
Office Visits | 3 | 2006 | 595 | 0.140 |
Why?
|
Arthritis, Rheumatoid | 2 | 2023 | 3733 | 0.140 |
Why?
|
Pyrazines | 2 | 2014 | 1204 | 0.140 |
Why?
|
Urothelium | 1 | 2019 | 272 | 0.140 |
Why?
|
Analgesics, Opioid | 2 | 2010 | 3835 | 0.140 |
Why?
|
Herpes Zoster Vaccine | 1 | 2018 | 50 | 0.140 |
Why?
|
Fatigue | 4 | 2023 | 1549 | 0.140 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2024 | 1376 | 0.140 |
Why?
|
Sarcoma | 2 | 2020 | 1802 | 0.140 |
Why?
|
Oximes | 1 | 2018 | 305 | 0.140 |
Why?
|
Liver Function Tests | 1 | 2018 | 525 | 0.140 |
Why?
|
Drug Resistance | 2 | 2020 | 1591 | 0.130 |
Why?
|
Immunization, Secondary | 1 | 2019 | 373 | 0.130 |
Why?
|
Cost Savings | 6 | 2017 | 904 | 0.130 |
Why?
|
Hematologic Diseases | 2 | 2018 | 500 | 0.130 |
Why?
|
Blast Crisis | 1 | 2017 | 102 | 0.130 |
Why?
|
Stroke | 4 | 2018 | 9747 | 0.130 |
Why?
|
Prognosis | 10 | 2023 | 29922 | 0.130 |
Why?
|
Sample Size | 1 | 2020 | 845 | 0.130 |
Why?
|
Poisson Distribution | 3 | 2018 | 508 | 0.130 |
Why?
|
Propensity Score | 6 | 2022 | 1968 | 0.130 |
Why?
|
Alzheimer Disease | 2 | 2024 | 8730 | 0.130 |
Why?
|
Adrenergic alpha-Antagonists | 1 | 2016 | 170 | 0.130 |
Why?
|
Injections, Intramuscular | 2 | 2016 | 552 | 0.130 |
Why?
|
Dementia | 1 | 2010 | 2744 | 0.130 |
Why?
|
Pyrimidinones | 1 | 2018 | 384 | 0.130 |
Why?
|
Immunoconjugates | 1 | 2023 | 981 | 0.130 |
Why?
|
Finasteride | 1 | 2016 | 86 | 0.130 |
Why?
|
Anti-Bacterial Agents | 4 | 2024 | 7478 | 0.120 |
Why?
|
Employment | 2 | 2020 | 1106 | 0.120 |
Why?
|
Bayes Theorem | 1 | 2023 | 2354 | 0.120 |
Why?
|
Diabetes Mellitus | 2 | 2018 | 5891 | 0.120 |
Why?
|
Cytomegalovirus Infections | 1 | 2022 | 836 | 0.120 |
Why?
|
Medical Records, Problem-Oriented | 1 | 2014 | 35 | 0.120 |
Why?
|
Intrauterine Devices | 1 | 2016 | 115 | 0.120 |
Why?
|
Palmitates | 1 | 2015 | 68 | 0.120 |
Why?
|
Hemorrhage | 3 | 2018 | 3461 | 0.120 |
Why?
|
Escherichia coli | 2 | 2024 | 4214 | 0.120 |
Why?
|
Drug Industry | 1 | 2021 | 791 | 0.120 |
Why?
|
Prostatic Neoplasms | 3 | 2024 | 11083 | 0.120 |
Why?
|
Risk | 6 | 2013 | 9591 | 0.120 |
Why?
|
Contraception Behavior | 1 | 2016 | 185 | 0.120 |
Why?
|
Oxygen Inhalation Therapy | 1 | 2018 | 418 | 0.110 |
Why?
|
Purpura, Thrombocytopenic, Idiopathic | 1 | 2018 | 245 | 0.110 |
Why?
|
Chronic Disease | 5 | 2018 | 9347 | 0.110 |
Why?
|
Blood Glucose | 3 | 2018 | 6424 | 0.110 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2017 | 660 | 0.110 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2017 | 238 | 0.110 |
Why?
|
Community Health Services | 3 | 2017 | 657 | 0.110 |
Why?
|
Fragile X Syndrome | 1 | 2015 | 116 | 0.110 |
Why?
|
Models, Econometric | 1 | 2014 | 213 | 0.110 |
Why?
|
Estradiol | 2 | 2018 | 1947 | 0.110 |
Why?
|
Lymphoma, B-Cell | 1 | 2021 | 943 | 0.110 |
Why?
|
United States Food and Drug Administration | 3 | 2021 | 1672 | 0.110 |
Why?
|
Antibodies, Neutralizing | 1 | 2024 | 2010 | 0.110 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2018 | 587 | 0.110 |
Why?
|
Infusions, Intravenous | 2 | 2009 | 2229 | 0.110 |
Why?
|
Postoperative Period | 1 | 2018 | 1816 | 0.110 |
Why?
|
Atrial Fibrillation | 1 | 2012 | 5189 | 0.110 |
Why?
|
Reproducibility of Results | 4 | 2023 | 20124 | 0.110 |
Why?
|
Brain Neoplasms | 1 | 2014 | 9071 | 0.110 |
Why?
|
Prednisone | 2 | 2021 | 1565 | 0.110 |
Why?
|
Isoxazoles | 1 | 2015 | 234 | 0.110 |
Why?
|
Trace Elements | 1 | 2014 | 193 | 0.110 |
Why?
|
Antifungal Agents | 1 | 2018 | 769 | 0.110 |
Why?
|
Cyclophosphamide | 3 | 2021 | 2228 | 0.100 |
Why?
|
Primary Myelofibrosis | 1 | 2015 | 210 | 0.100 |
Why?
|
Medicare Part D | 1 | 2018 | 355 | 0.100 |
Why?
|
Technology Assessment, Biomedical | 1 | 2015 | 312 | 0.100 |
Why?
|
Logistic Models | 4 | 2021 | 13266 | 0.100 |
Why?
|
Immunoglobulin G | 1 | 2024 | 4528 | 0.100 |
Why?
|
Contraceptive Agents | 1 | 2014 | 147 | 0.100 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2022 | 5753 | 0.100 |
Why?
|
Long-Term Care | 2 | 2017 | 629 | 0.100 |
Why?
|
Secondary Prevention | 2 | 2018 | 1472 | 0.100 |
Why?
|
Vincristine | 2 | 2021 | 1039 | 0.100 |
Why?
|
Therapeutic Equivalency | 2 | 2009 | 134 | 0.100 |
Why?
|
Biological Products | 1 | 2021 | 942 | 0.100 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 689 | 0.100 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2021 | 3513 | 0.100 |
Why?
|
Hot Flashes | 1 | 2015 | 330 | 0.100 |
Why?
|
Asia | 1 | 2013 | 628 | 0.100 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2013 | 187 | 0.100 |
Why?
|
Caregivers | 2 | 2015 | 2307 | 0.100 |
Why?
|
Health Benefit Plans, Employee | 2 | 2012 | 331 | 0.090 |
Why?
|
Hydroxyurea | 1 | 2013 | 284 | 0.090 |
Why?
|
Lymphoma | 1 | 2021 | 1897 | 0.090 |
Why?
|
Child, Preschool | 8 | 2017 | 42500 | 0.090 |
Why?
|
Organ Transplantation | 1 | 2022 | 1174 | 0.090 |
Why?
|
Outpatients | 3 | 2016 | 1595 | 0.090 |
Why?
|
Lymphatic Metastasis | 1 | 2019 | 2887 | 0.090 |
Why?
|
Melphalan | 1 | 2013 | 425 | 0.090 |
Why?
|
Prediabetic State | 1 | 2017 | 548 | 0.090 |
Why?
|
Topotecan | 2 | 2008 | 130 | 0.090 |
Why?
|
Venous Thrombosis | 2 | 2018 | 1327 | 0.090 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2019 | 961 | 0.090 |
Why?
|
Glomerular Filtration Rate | 4 | 2018 | 2233 | 0.090 |
Why?
|
Oncology Service, Hospital | 1 | 2011 | 55 | 0.090 |
Why?
|
Receptors, Androgen | 1 | 2017 | 1088 | 0.090 |
Why?
|
Guideline Adherence | 1 | 2021 | 2243 | 0.090 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2021 | 1434 | 0.090 |
Why?
|
Hydrocodone | 1 | 2010 | 48 | 0.090 |
Why?
|
Drug Utilization Review | 1 | 2012 | 248 | 0.090 |
Why?
|
Amitriptyline | 1 | 2011 | 109 | 0.090 |
Why?
|
Disease-Free Survival | 5 | 2020 | 6832 | 0.090 |
Why?
|
Product Recalls and Withdrawals | 1 | 2010 | 7 | 0.090 |
Why?
|
Disabled Persons | 1 | 2020 | 1208 | 0.080 |
Why?
|
Blood Glucose Self-Monitoring | 1 | 2013 | 475 | 0.080 |
Why?
|
Pharmacy Service, Hospital | 2 | 2008 | 134 | 0.080 |
Why?
|
Adrenergic Uptake Inhibitors | 1 | 2011 | 187 | 0.080 |
Why?
|
Medical Oncology | 1 | 2021 | 2339 | 0.080 |
Why?
|
Filgrastim | 1 | 2009 | 131 | 0.080 |
Why?
|
Suicidal Ideation | 1 | 2020 | 1461 | 0.080 |
Why?
|
Infant | 7 | 2017 | 36386 | 0.080 |
Why?
|
Drug Prescriptions | 3 | 2008 | 1662 | 0.080 |
Why?
|
Cross-Sectional Studies | 5 | 2022 | 26318 | 0.080 |
Why?
|
Upper Gastrointestinal Tract | 1 | 2009 | 46 | 0.080 |
Why?
|
Schizophrenic Psychology | 1 | 2016 | 1648 | 0.080 |
Why?
|
Cyclopropanes | 1 | 2011 | 437 | 0.080 |
Why?
|
Oxycodone | 1 | 2010 | 143 | 0.080 |
Why?
|
Multiple Sclerosis | 2 | 2015 | 3213 | 0.080 |
Why?
|
Markov Chains | 1 | 2013 | 968 | 0.080 |
Why?
|
Recombinant Fusion Proteins | 1 | 2017 | 3737 | 0.080 |
Why?
|
Italy | 1 | 2011 | 854 | 0.080 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2017 | 1534 | 0.080 |
Why?
|
Socioeconomic Factors | 4 | 2016 | 7838 | 0.080 |
Why?
|
Risk Assessment | 6 | 2018 | 24282 | 0.080 |
Why?
|
Confidence Intervals | 2 | 2012 | 2910 | 0.080 |
Why?
|
Stem Cell Transplantation | 1 | 2017 | 1602 | 0.080 |
Why?
|
Netherlands | 3 | 2018 | 2277 | 0.070 |
Why?
|
Down Syndrome | 1 | 2016 | 915 | 0.070 |
Why?
|
Anti-Arrhythmia Agents | 1 | 2012 | 769 | 0.070 |
Why?
|
Doxorubicin | 2 | 2021 | 2230 | 0.070 |
Why?
|
Tobramycin | 1 | 2008 | 65 | 0.070 |
Why?
|
Menopause | 1 | 2016 | 1659 | 0.070 |
Why?
|
Combined Modality Therapy | 1 | 2020 | 8529 | 0.070 |
Why?
|
Drug Utilization | 3 | 2010 | 1187 | 0.070 |
Why?
|
Genetic Testing | 1 | 2021 | 3595 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2023 | 10383 | 0.070 |
Why?
|
Infant, Newborn | 4 | 2017 | 26346 | 0.070 |
Why?
|
Double-Blind Method | 1 | 2022 | 12437 | 0.070 |
Why?
|
Salvage Therapy | 1 | 2014 | 1272 | 0.070 |
Why?
|
Disease Management | 2 | 2016 | 2535 | 0.070 |
Why?
|
Antiviral Agents | 3 | 2022 | 3050 | 0.070 |
Why?
|
Thalidomide | 1 | 2013 | 886 | 0.070 |
Why?
|
Databases as Topic | 1 | 2009 | 471 | 0.070 |
Why?
|
Sickness Impact Profile | 1 | 2008 | 297 | 0.070 |
Why?
|
Philadelphia Chromosome | 2 | 2018 | 119 | 0.070 |
Why?
|
Glucocorticoids | 1 | 2016 | 2132 | 0.070 |
Why?
|
Public Health | 2 | 2017 | 2680 | 0.070 |
Why?
|
Utilization Review | 1 | 2008 | 381 | 0.070 |
Why?
|
Boston | 1 | 2020 | 9338 | 0.070 |
Why?
|
Critical Care | 2 | 2018 | 2712 | 0.070 |
Why?
|
Models, Statistical | 2 | 2019 | 5089 | 0.070 |
Why?
|
Somatostatinoma | 1 | 2006 | 10 | 0.070 |
Why?
|
Analgesics, Non-Narcotic | 1 | 2010 | 366 | 0.070 |
Why?
|
Pancreatic Neoplasms | 3 | 2017 | 5444 | 0.070 |
Why?
|
Etoposide | 1 | 2008 | 636 | 0.070 |
Why?
|
Prenatal Care | 1 | 2014 | 1160 | 0.060 |
Why?
|
Decision Making | 1 | 2020 | 3965 | 0.060 |
Why?
|
Gastrointestinal Diseases | 2 | 2016 | 1203 | 0.060 |
Why?
|
Regression Analysis | 4 | 2019 | 6322 | 0.060 |
Why?
|
Florida | 2 | 2018 | 416 | 0.060 |
Why?
|
Insurance Claim Reporting | 3 | 2016 | 166 | 0.060 |
Why?
|
Goserelin | 1 | 2006 | 126 | 0.060 |
Why?
|
Seizures | 1 | 2018 | 3000 | 0.060 |
Why?
|
Anemia, Iron-Deficiency | 1 | 2009 | 374 | 0.060 |
Why?
|
Hospitals | 1 | 2018 | 3888 | 0.060 |
Why?
|
Excitatory Amino Acid Antagonists | 1 | 2007 | 450 | 0.060 |
Why?
|
Delivery of Health Care | 3 | 2023 | 5370 | 0.060 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2008 | 878 | 0.060 |
Why?
|
Carboplatin | 1 | 2008 | 789 | 0.060 |
Why?
|
Rotavirus | 2 | 2016 | 110 | 0.060 |
Why?
|
Sleep | 1 | 2020 | 4813 | 0.060 |
Why?
|
Pregnancy | 3 | 2016 | 30260 | 0.060 |
Why?
|
Embolization, Therapeutic | 3 | 2019 | 1403 | 0.060 |
Why?
|
Leukocyte Count | 2 | 2018 | 1602 | 0.060 |
Why?
|
Camptothecin | 1 | 2008 | 600 | 0.060 |
Why?
|
Odds Ratio | 2 | 2016 | 9649 | 0.060 |
Why?
|
Patient Readmission | 2 | 2016 | 3286 | 0.060 |
Why?
|
Fractures, Spontaneous | 1 | 2006 | 230 | 0.060 |
Why?
|
Leuprolide | 1 | 2006 | 312 | 0.060 |
Why?
|
Diabetic Angiopathies | 1 | 2009 | 805 | 0.060 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2019 | 4044 | 0.060 |
Why?
|
Polyethylene Glycols | 1 | 2009 | 1188 | 0.060 |
Why?
|
Acute Disease | 1 | 2014 | 7232 | 0.050 |
Why?
|
Insulin | 1 | 2018 | 6599 | 0.050 |
Why?
|
Intestinal Neoplasms | 1 | 2006 | 313 | 0.050 |
Why?
|
Patient Participation | 1 | 2013 | 1455 | 0.050 |
Why?
|
Length of Stay | 4 | 2015 | 6485 | 0.050 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2008 | 451 | 0.050 |
Why?
|
Drug Therapy | 1 | 2006 | 504 | 0.050 |
Why?
|
Alkaline Phosphatase | 1 | 2006 | 854 | 0.050 |
Why?
|
Creatinine | 1 | 2008 | 1915 | 0.050 |
Why?
|
Agammaglobulinemia | 1 | 2024 | 173 | 0.050 |
Why?
|
Health Services Needs and Demand | 1 | 2010 | 1406 | 0.050 |
Why?
|
Aromatase Inhibitors | 1 | 2006 | 518 | 0.050 |
Why?
|
Predictive Value of Tests | 2 | 2016 | 15398 | 0.050 |
Why?
|
Neoplasm Proteins | 1 | 2014 | 3596 | 0.050 |
Why?
|
Immunization, Passive | 1 | 2024 | 616 | 0.050 |
Why?
|
Licensure, Pharmacy | 1 | 2021 | 2 | 0.050 |
Why?
|
Cisplatin | 1 | 2008 | 1658 | 0.050 |
Why?
|
Prospective Studies | 5 | 2023 | 54802 | 0.050 |
Why?
|
Delayed-Action Preparations | 2 | 2016 | 967 | 0.050 |
Why?
|
Fluoroquinolones | 1 | 2023 | 307 | 0.050 |
Why?
|
Tryptases | 1 | 2022 | 177 | 0.050 |
Why?
|
Endpoint Determination | 2 | 2015 | 591 | 0.050 |
Why?
|
Inpatients | 2 | 2016 | 2564 | 0.050 |
Why?
|
C-Reactive Protein | 2 | 2023 | 3850 | 0.050 |
Why?
|
Germany | 1 | 2023 | 882 | 0.050 |
Why?
|
Area Under Curve | 1 | 2005 | 1638 | 0.050 |
Why?
|
Constipation | 1 | 2006 | 568 | 0.050 |
Why?
|
Health Care Surveys | 2 | 2022 | 2424 | 0.040 |
Why?
|
Substance-Related Disorders | 1 | 2017 | 4416 | 0.040 |
Why?
|
Psoriasis | 1 | 2008 | 919 | 0.040 |
Why?
|
Psychotic Disorders | 1 | 2016 | 3270 | 0.040 |
Why?
|
Arthroplasty, Replacement, Hip | 1 | 2011 | 1416 | 0.040 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2016 | 3646 | 0.040 |
Why?
|
Insurance Coverage | 1 | 2012 | 1944 | 0.040 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2024 | 660 | 0.040 |
Why?
|
Arthroplasty, Replacement, Knee | 1 | 2011 | 1379 | 0.040 |
Why?
|
Hospital Mortality | 1 | 2014 | 5343 | 0.040 |
Why?
|
Irritable Bowel Syndrome | 1 | 2006 | 454 | 0.040 |
Why?
|
Forecasting | 1 | 2009 | 2936 | 0.040 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 2006 | 1133 | 0.040 |
Why?
|
Budesonide | 1 | 2021 | 163 | 0.040 |
Why?
|
Prostate-Specific Antigen | 2 | 2024 | 2464 | 0.040 |
Why?
|
Data Collection | 2 | 2006 | 3318 | 0.040 |
Why?
|
Physician's Role | 1 | 2006 | 927 | 0.040 |
Why?
|
Health Records, Personal | 1 | 2020 | 126 | 0.040 |
Why?
|
Drug Resistance, Multiple, Bacterial | 1 | 2024 | 592 | 0.040 |
Why?
|
Hemolysis | 1 | 2021 | 406 | 0.040 |
Why?
|
Colchicine | 1 | 2020 | 256 | 0.040 |
Why?
|
Electrocardiography | 1 | 2012 | 6404 | 0.040 |
Why?
|
Hepatitis B virus | 1 | 2022 | 530 | 0.040 |
Why?
|
Radiopharmaceuticals | 2 | 2019 | 2699 | 0.040 |
Why?
|
Indazoles | 1 | 2020 | 303 | 0.040 |
Why?
|
Antidepressive Agents | 1 | 2011 | 2897 | 0.040 |
Why?
|
Academic Medical Centers | 2 | 2021 | 2780 | 0.040 |
Why?
|
Narcotics | 1 | 2020 | 332 | 0.040 |
Why?
|
Anthracyclines | 1 | 2020 | 284 | 0.040 |
Why?
|
Tablets | 1 | 2019 | 149 | 0.040 |
Why?
|
Oligopeptides | 1 | 2024 | 1192 | 0.040 |
Why?
|
Pneumonia | 2 | 2014 | 2157 | 0.040 |
Why?
|
Psychometrics | 1 | 2007 | 3062 | 0.040 |
Why?
|
Vaccines, Conjugate | 1 | 2019 | 334 | 0.040 |
Why?
|
Colon | 1 | 2006 | 1795 | 0.040 |
Why?
|
Adenine | 1 | 2023 | 994 | 0.040 |
Why?
|
Linear Models | 2 | 2019 | 5876 | 0.040 |
Why?
|
Receptors, Thrombopoietin | 1 | 2018 | 157 | 0.040 |
Why?
|
Microbial Sensitivity Tests | 1 | 2024 | 1971 | 0.040 |
Why?
|
Flushing | 1 | 2017 | 52 | 0.030 |
Why?
|
Community Health Centers | 1 | 2021 | 469 | 0.030 |
Why?
|
Decision Trees | 1 | 2019 | 509 | 0.030 |
Why?
|
Ischemia | 1 | 2006 | 1909 | 0.030 |
Why?
|
Prevalence | 4 | 2022 | 15842 | 0.030 |
Why?
|
Methotrexate | 1 | 2023 | 1722 | 0.030 |
Why?
|
Uracil | 1 | 2018 | 210 | 0.030 |
Why?
|
Intensive Care Units | 3 | 2007 | 3800 | 0.030 |
Why?
|
Osteoporosis | 1 | 2006 | 1582 | 0.030 |
Why?
|
Drug Resistance, Bacterial | 1 | 2024 | 1069 | 0.030 |
Why?
|
Sex Distribution | 2 | 2015 | 2263 | 0.030 |
Why?
|
Kidney Function Tests | 1 | 2018 | 683 | 0.030 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2020 | 2268 | 0.030 |
Why?
|
Kansas | 1 | 2016 | 37 | 0.030 |
Why?
|
Iowa | 1 | 2016 | 100 | 0.030 |
Why?
|
Deoxycytidine | 1 | 2020 | 889 | 0.030 |
Why?
|
Mississippi | 1 | 2016 | 93 | 0.030 |
Why?
|
Ferritins | 1 | 2019 | 600 | 0.030 |
Why?
|
Rare Diseases | 1 | 2021 | 635 | 0.030 |
Why?
|
Platelet Count | 1 | 2018 | 782 | 0.030 |
Why?
|
Age Distribution | 2 | 2015 | 2858 | 0.030 |
Why?
|
Drug Substitution | 1 | 2018 | 292 | 0.030 |
Why?
|
Injections, Subcutaneous | 1 | 2017 | 682 | 0.030 |
Why?
|
Retreatment | 1 | 2017 | 598 | 0.030 |
Why?
|
Direct Service Costs | 1 | 2015 | 61 | 0.030 |
Why?
|
Advisory Committees | 1 | 2019 | 796 | 0.030 |
Why?
|
Cross Infection | 1 | 2004 | 1427 | 0.030 |
Why?
|
Critical Illness | 2 | 2007 | 2744 | 0.030 |
Why?
|
Case Management | 1 | 2016 | 277 | 0.030 |
Why?
|
Interferon-alpha | 1 | 2019 | 910 | 0.030 |
Why?
|
Matched-Pair Analysis | 1 | 2015 | 284 | 0.030 |
Why?
|
Epilepsies, Partial | 1 | 2018 | 431 | 0.030 |
Why?
|
Drug Approval | 1 | 2021 | 818 | 0.030 |
Why?
|
Kidney | 1 | 2010 | 7066 | 0.030 |
Why?
|
Fractures, Bone | 1 | 2006 | 2041 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2012 | 22223 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2020 | 5337 | 0.030 |
Why?
|
Health Status | 2 | 2018 | 4080 | 0.030 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2019 | 1237 | 0.030 |
Why?
|
Cholesterol | 1 | 2023 | 2898 | 0.030 |
Why?
|
Organ Size | 1 | 2018 | 2260 | 0.030 |
Why?
|
Data Mining | 1 | 2018 | 562 | 0.030 |
Why?
|
Forced Expiratory Volume | 1 | 2018 | 1828 | 0.030 |
Why?
|
Patient-Centered Care | 1 | 2023 | 1458 | 0.030 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2019 | 1061 | 0.030 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2019 | 1514 | 0.030 |
Why?
|
Nephrectomy | 1 | 2018 | 927 | 0.030 |
Why?
|
Respiration, Artificial | 1 | 2004 | 2709 | 0.030 |
Why?
|
Respiratory Function Tests | 1 | 2017 | 1693 | 0.020 |
Why?
|
Tumor Burden | 1 | 2018 | 1885 | 0.020 |
Why?
|
DNA Repair | 1 | 2021 | 2048 | 0.020 |
Why?
|
Spain | 1 | 2013 | 483 | 0.020 |
Why?
|
Aging | 1 | 2010 | 8731 | 0.020 |
Why?
|
Injections | 1 | 2014 | 840 | 0.020 |
Why?
|
Nutrition Surveys | 1 | 2018 | 1741 | 0.020 |
Why?
|
Sulfonamides | 1 | 2020 | 1984 | 0.020 |
Why?
|
Primary Prevention | 1 | 2018 | 1187 | 0.020 |
Why?
|
Liver Neoplasms | 1 | 2006 | 4353 | 0.020 |
Why?
|
Pain Measurement | 1 | 2020 | 3561 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2018 | 3537 | 0.020 |
Why?
|
Medical Audit | 1 | 2011 | 452 | 0.020 |
Why?
|
Internet | 1 | 2021 | 3106 | 0.020 |
Why?
|
Anemia, Refractory | 1 | 2008 | 17 | 0.020 |
Why?
|
Pyrimidines | 1 | 2020 | 3047 | 0.020 |
Why?
|
Computer Simulation | 2 | 2014 | 6255 | 0.020 |
Why?
|
Decision Support Techniques | 1 | 2018 | 2003 | 0.020 |
Why?
|
Transplantation, Homologous | 1 | 2017 | 4860 | 0.020 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2014 | 712 | 0.020 |
Why?
|
Nursing Service, Hospital | 1 | 2008 | 17 | 0.020 |
Why?
|
Liver Failure, Acute | 1 | 2010 | 183 | 0.020 |
Why?
|
Blood Platelets | 1 | 2018 | 2464 | 0.020 |
Why?
|
Analysis of Variance | 2 | 2006 | 6203 | 0.020 |
Why?
|
Health Services Accessibility | 2 | 2018 | 5508 | 0.020 |
Why?
|
Anemia, Sideroblastic | 1 | 2008 | 106 | 0.020 |
Why?
|
Morbidity | 1 | 2012 | 1749 | 0.020 |
Why?
|
Blood Donors | 1 | 2009 | 342 | 0.020 |
Why?
|
Drug Evaluation | 1 | 2008 | 641 | 0.020 |
Why?
|
Myeloproliferative Disorders | 1 | 2013 | 616 | 0.020 |
Why?
|
Hematocrit | 1 | 2008 | 621 | 0.020 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2016 | 6014 | 0.020 |
Why?
|
Self-Assessment | 1 | 2008 | 400 | 0.020 |
Why?
|
Ontario | 1 | 2007 | 402 | 0.020 |
Why?
|
Anxiety | 1 | 2020 | 4671 | 0.020 |
Why?
|
Stress, Psychological | 1 | 2020 | 4533 | 0.020 |
Why?
|
Cholesterol, LDL | 1 | 2014 | 2393 | 0.010 |
Why?
|
Quality-Adjusted Life Years | 1 | 2012 | 1737 | 0.010 |
Why?
|
Ultrasonography | 1 | 2018 | 5993 | 0.010 |
Why?
|
Insurance, Pharmaceutical Services | 1 | 2007 | 347 | 0.010 |
Why?
|
Bilirubin | 1 | 2006 | 439 | 0.010 |
Why?
|
Coronary Disease | 1 | 2018 | 5912 | 0.010 |
Why?
|
Multicenter Studies as Topic | 1 | 2008 | 1731 | 0.010 |
Why?
|
Observation | 1 | 2004 | 309 | 0.010 |
Why?
|
Blood Chemical Analysis | 1 | 2004 | 433 | 0.010 |
Why?
|
Hospital Costs | 1 | 2008 | 956 | 0.010 |
Why?
|
Mental Health | 1 | 2015 | 3278 | 0.010 |
Why?
|
Phenotype | 1 | 2018 | 16721 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2006 | 21056 | 0.010 |
Why?
|
Pulmonary Embolism | 1 | 2012 | 2598 | 0.010 |
Why?
|
Probability | 1 | 2004 | 2475 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2014 | 8041 | 0.010 |
Why?
|
Animals | 1 | 2008 | 168764 | 0.010 |
Why?
|
Anticoagulants | 1 | 2011 | 4862 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2018 | 20659 | 0.010 |
Why?
|
Palliative Care | 1 | 2008 | 3645 | 0.010 |
Why?
|
Massachusetts | 1 | 2006 | 8875 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 2011 | 11499 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2011 | 15747 | 0.000 |
Why?
|